Effect of Acetylcholinesterase Inhibitors on Bone Metabolism - Trial NCT06041789
Access comprehensive clinical trial information for NCT06041789 through Pure Global AI's free database. This Phase 2 trial is sponsored by Duke University and is currently Not yet recruiting. The study focuses on Osteoporosis. Target enrollment is 45 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Duke University
Timeline & Enrollment
Phase 2
Dec 04, 2023
Mar 01, 2025
Primary Outcome
Change in bone mineral density, as measured by dual x-ray absorptiometry (DXA)
Summary
People with Alzheimer's disease are at an increased risk of bone fracture. Some studies have
 shown that those taking donepezil have a lower rate of bone fractures, but the reasons for
 this are unknown. The purpose of this study is to measure the effect of donepezil treatment
 on bone metabolism factors including bone mineral density, bone turnover markers, and bone
 quality.
 
 Participants in this study will have a bone density test and have blood samples collected at
 the baseline study visit. Participants will then be randomly assigned to donepezil or
 matching placebo to be taken daily by mouth for 12 months. Blood samples will be collected at
 6 and 12 months. A repeat bone density test will be performed at 12 months. Participants will
 also complete questionnaires at each study visit.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06041789
Non-Device Trial